Angiogenic peptides and uses thereof

Abstract

A peptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, 4, 6, 8, 10 or 12 is provided. The peptide being at least 6 and no more than 50 amino acid residues in length. Also provided are therapeutic applications using such peptides.

1 .- 69 . (canceled) 
     
     
         70 . A method of promoting angiogenesis in a tissue of a subject, the method comprising providing to the subject a therapeutically effective amount of a peptide comprising the amino acid sequence set forth in SEQ ID NO:2, 6, 10 or 12, said peptide is no more than 50 amino acids in length, thereby promoting angiogenesis in the subject. 
     
     
         71 . A method of promoting angiogenesis in a tissue of a subject, the method comprising providing to the subject a therapeutically effective amount of a peptide consisting of the amino acid sequence set forth in SEQ ID NO:2, 6, 10 or 12, thereby promoting angiogenesis in the subject. 
     
     
         72 . A method of promoting angiogenesis in a tissue of a subject, the method comprising providing to the subject a therapeutically effective amount of at least two peptides each independently selected from the group consisting of SEQ ID NO:2, 4, 6, 10 and 12, thereby promoting angiogenesis in the subject. 
     
     
         73 . A method of promoting angiogenesis in a tissue of a subject, the method comprising providing to the subject a therapeutically effective amount of at least two peptides each independently selected from the group consisting of SEQ ID NO:2, 6, 8, 10 and 12, thereby promoting angiogenesis in the subject. 
     
     
         74 . The method of  claim 70 , wherein said peptide is a cyclic peptide and whereas said amino acid sequence is selected from the group consisting of SEQ ID NOs:2, 6, 10 and 12. 
     
     
         75 . The method of  claim 70 , wherein the subject suffers from delayed wound-healing, delayed ulcer healing, reproduction associated disorders, coronary artery disease, arteriosclerosis, myocardial ischemia, peripheral ischemia, cerebral ischemia, retinopathy, remodeling disorder, von Hippel-Lindau syndrome, diabetes and/or hereditary hemorrhagic telengiectasia. 
     
     
         76 . The method of  claim 71 , wherein the subject suffers from delayed wound-healing, delayed ulcer healing, reproduction associated disorders, coronary artery disease, arteriosclerosis, myocardial ischemia, peripheral ischemia, cerebral ischemia, retinopathy, remodeling disorder, von Hippel-Lindau syndrome, diabetes and/or hereditary hemorrhagic telengiectasia. 
     
     
         77 . The method of  claim 72 , wherein the subject suffers from delayed wound-healing, delayed ulcer healing, reproduction associated disorders, coronary artery disease, arteriosclerosis, myocardial ischemia, peripheral ischemia, cerebral ischemia, retinopathy, remodeling disorder, von Hippel-Lindau syndrome, diabetes and/or hereditary hemorrhagic telengiectasia. 
     
     
         78 . The method of  claim 70 , wherein the tissue is vascular tissue. 
     
     
         79 . The method of  claim 71 , wherein the tissue is vascular tissue. 
     
     
         80 . The method of  claim 72 , wherein the tissue is vascular tissue. 
     
     
         81 . A nucleic acid construct comprising a polynucleotide sequence encoding a peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 6 and 10. 
     
     
         82 . The nucleic acid construct of  claim 81 , further comprising a promoter. 
     
     
         83 . A nucleic acid construct comprising a polynucleotide sequence encoding a peptide comprising the amino acid sequence as set forth in SEQ ID NO:13, 27 or 32, the peptide being at least 6 and no more than 50 amino acid residues in length. 
     
     
         84 . The nucleic acid construct of  claim 83 , further comprising a promoter. 
     
     
         85 . A method of identifying putative angiogenic molecules, the method comprising:
 (a) providing endothelial cells having peptides bound thereto, each of said peptides having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10 and 12, said peptide being no more than 50 amino acid residues in length; and   (b) identifying a molecule capable of displacing said peptides from said endothelial cells, to thereby identify putative angiogenic molecules.   
     
     
         86 . A cyclic peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:2 and 12, the peptide being no more than 50 amino acid residues in length. 
     
     
         87 . A composition for targeting a drug to endothelial cells, the composition comprising the drug fused to the cyclic peptide of  claim 86 . 
     
     
         88 . A pharmaceutical composition comprising as an active ingredient the cyclic peptide of  claim 86  and a pharmaceutically acceptable carrier or diluent. 
     
     
         89 . A peptide comprising the amino acid sequence as set forth in SEQ ID NO:27 or 32, wherein the peptide being at least 6 and no more than 50 amino acid residues in length. 
     
     
         90 . The peptide of  claim 89 , being cyclic. 
     
     
         91 . The cyclic peptide of  claim 90 , wherein the amino acid sequence is set forth by SEQ ID NO:2 or 12. 
     
     
         92 . A composition for targeting a drug to endothelial cells, the composition comprising the drug fused to the peptide of  claim 89 . 
     
     
         93 . A pharmaceutical composition comprising as an active ingredient the peptide of  claim 89  and a pharmaceutically acceptable carrier or diluent.